Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 43

1.

The role of RICTOR downstream of receptor tyrosine kinase in cancers.

Jebali A, Dumaz N.

Mol Cancer. 2018 Feb 19;17(1):39. doi: 10.1186/s12943-018-0794-0. Review.

2.

Mutations causing acrodysostosis-2 facilitate activation of phosphodiesterase 4D3.

Briet C, Pereda A, Le Stunff C, Motte E, de Dios Garcia-Diaz J, de Nanclares GP, Dumaz N, Silve C.

Hum Mol Genet. 2017 Oct 15;26(20):3883-3894. doi: 10.1093/hmg/ddx271.

PMID:
29016851
3.

STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network.

Delyon J, Chevret S, Jouary T, Dalac S, Dalle S, Guillot B, Arnault JP, Avril MF, Bedane C, Bens G, Pham-Ledard A, Mansard S, Grange F, Machet L, Meyer N, Legoupil D, Saiag P, Idir Z, Renault V, Deleuze JF, Hindie E, Battistella M, Dumaz N, Mourah S, Lebbe C; GCC (French Group of Skin Cancer).

J Invest Dermatol. 2018 Jan;138(1):58-67. doi: 10.1016/j.jid.2017.07.839. Epub 2017 Aug 24.

PMID:
28843487
4.

PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma.

Delyon J, Servy A, Laugier F, André J, Ortonne N, Battistella M, Mourah S, Bensussan A, Lebbé C, Dumaz N.

Oncogene. 2017 Jun 8;36(23):3252-3262. doi: 10.1038/onc.2016.469. Epub 2017 Jan 16.

PMID:
28092671
5.

Modulation of signaling through GPCR-cAMP-PKA pathways by PDE4 depends on stimulus intensity: Possible implications for the pathogenesis of acrodysostosis without hormone resistance.

Motte E, Le Stunff C, Briet C, Dumaz N, Silve C.

Mol Cell Endocrinol. 2017 Feb 15;442:1-11. doi: 10.1016/j.mce.2016.11.026. Epub 2016 Nov 28.

PMID:
27908835
6.

Correction: Validation of a preclinical model for assessment of drug efficacy in melanoma.

Delyon J, Varna M, Feugeas JP, Sadoux A, Yahiaoui S, Podgorniak MP, Leclert G, Mazouz Dorval S, Dumaz N, Janin A, Mourah S, Lebbé C.

Oncotarget. 2016 Jul 26;7(30):48850. doi: 10.18632/oncotarget.10822. No abstract available.

7.

TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation.

Vallarelli AF, Rachakonda PS, André J, Heidenreich B, Riffaud L, Bensussan A, Kumar R, Dumaz N.

Oncotarget. 2016 Aug 16;7(33):53127-53136. doi: 10.18632/oncotarget.10634.

8.

Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles.

Eisenhardt AE, Sprenger A, Röring M, Herr R, Weinberg F, Köhler M, Braun S, Orth J, Diedrich B, Lanner U, Tscherwinski N, Schuster S, Dumaz N, Schmidt E, Baumeister R, Schlosser A, Dengjel J, Brummer T.

Oncotarget. 2016 May 3;7(18):26628-52. doi: 10.18632/oncotarget.8427.

9.

Hypoxia and MITF regulate KIT oncogenic properties in melanocytes.

Laugier F, Delyon J, André J, Bensussan A, Dumaz N.

Oncogene. 2016 Sep 22;35(38):5070-7. doi: 10.1038/onc.2016.39. Epub 2016 Mar 14.

PMID:
26973244
10.

Validation of a preclinical model for assessment of drug efficacy in melanoma.

Delyon J, Varna M, Feugeas JP, Sadoux A, Yahiaoui S, Podgorniak MP, Leclert G, Dorval SM, Dumaz N, Soulie J, Janin A, Mourah S, Lebbé C.

Oncotarget. 2016 Mar 15;7(11):13069-81. doi: 10.18632/oncotarget.7541. Erratum in: Oncotarget. 2016 Jul 26;7(30):48850. Soulie, J [added].

11.

Association of Vemurafenib and Pipobroman Enhances BRAF-CRAF Dimerization in Squamous Cell Carcinoma.

Cassius C, Pages C, Roux J, Lhote R, Lavocat R, Réa D, Bagot M, Mourah S, Battistella M, Lebbé C, Dumaz N.

J Invest Dermatol. 2016 Jun;136(6):1302-5. doi: 10.1016/j.jid.2015.12.047. Epub 2016 Feb 15. No abstract available.

12.

PARKIN Inactivation Links Parkinson's Disease to Melanoma.

Hu HH, Kannengiesser C, Lesage S, André J, Mourah S, Michel L, Descamps V, Basset-Seguin N, Bagot M, Bensussan A, Lebbé C, Deschamps L, Saiag P, Leccia MT, Bressac-de-Paillerets B, Tsalamlal A, Kumar R, Klebe S, Grandchamp B, Andrieu-Abadie N, Thomas L, Brice A, Dumaz N, Soufir N.

J Natl Cancer Inst. 2015 Dec 17;108(3). doi: 10.1093/jnci/djv340. Print 2016 Mar.

PMID:
26683220
13.

RICTOR involvement in the PI3K/AKT pathway regulation in melanocytes and melanoma.

Laugier F, Finet-Benyair A, André J, Rachakonda PS, Kumar R, Bensussan A, Dumaz N.

Oncotarget. 2015 Sep 29;6(29):28120-31. doi: 10.18632/oncotarget.4866.

14.

Driver KIT mutations in melanoma cluster in four hotspots.

Dumaz N, André J, Sadoux A, Laugier F, Podgorniak MP, Mourah S, Lebbé C.

Melanoma Res. 2015 Feb;25(1):88-90. doi: 10.1097/CMR.0000000000000116.

PMID:
25304235
15.

A large French case-control study emphasizes the role of rare Mc1R variants in melanoma risk.

Hu HH, Benfodda M, Dumaz N, Gazal S, Descamps V, Bourillon A, Basset-Seguin N, Riffault A, Ezzedine K, Bagot M, Bensussan A, Saiag P, Grandchamp B, Soufir N.

Biomed Res Int. 2014;2014:925716. doi: 10.1155/2014/925716. Epub 2014 Apr 10.

16.

A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib.

Allegra M, Giacchero D, Segalen C, Dumaz N, Butori C, Hofman V, Hofman P, Lacour JP, Bertolotto C, Bahadoran P, Ballotti R.

J Invest Dermatol. 2014 May;134(5):1473-1476. doi: 10.1038/jid.2013.525. Epub 2013 Dec 6. No abstract available.

17.

Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations.

Chraybi M, Abd Alsamad I, Copie-Bergman C, Baia M, André J, Dumaz N, Ortonne N.

Hum Pathol. 2013 Sep;44(9):1902-11. doi: 10.1016/j.humpath.2013.01.025. Epub 2013 May 9.

18.

Genetic variation at KIT locus may predispose to melanoma.

Bourillon A, Hu HH, Hetet G, Lacapere JJ, André J, Descamps V, Basset-Seguin N, Ogbah Z, Puig S, Saiag P, Bagot M, Bensussan A, Grandchamp B, Dumaz N, Soufir N.

Pigment Cell Melanoma Res. 2013 Jan;26(1):88-96. doi: 10.1111/pcmr.12032. Epub 2012 Nov 23.

PMID:
23020152
19.

Mechanism of RAF isoform switching induced by oncogenic RAS in melanoma.

Dumaz N.

Small GTPases. 2011 Sep;2(5):289-292. Epub 2011 Sep 1.

20.

Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.

Arnault JP, Mateus C, Escudier B, Tomasic G, Wechsler J, Hollville E, Soria JC, Malka D, Sarasin A, Larcher M, André J, Kamsu-Kom N, Boussemart L, Lacroix L, Spatz A, Eggermont AM, Druillennec S, Vagner S, Eychène A, Dumaz N, Robert C.

Clin Cancer Res. 2012 Jan 1;18(1):263-72. doi: 10.1158/1078-0432.CCR-11-1344. Epub 2011 Nov 17.

Supplemental Content

Support Center